文献速递免疫规划传染病防控与疫情报告

Ad26.COV2.S 在成人中的安全性和免疫原性:一项随机、双盲、安慰剂对照的 2a 期剂量探索研究

Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
PubMed 文献 · Vaccine · 2024-05-04

本随机、双盲、安慰剂对照 2a 期研究在 18-55 岁和 ≥65 岁成人中评估 Ad26.COV2.S 不同剂量、剂次和间隔的免疫原性、反应原性和安全性。结果显示所有方案均诱导体液免疫且呈剂量反应关系,单剂 5×10^10 vp 诱导的抗体和细胞免疫至少持续 6 个月,2 剂方案抗体反应高于单剂,间隔 84 天高于 56 天。研究支持单剂 5×10^10 vp 基础免疫及 6 个月后同源加强。

要点

  • 单剂 Ad26.COV2.S 5×10^10 vp 诱导的抗体和细胞免疫至少持续 6 个月。
  • 2 剂方案抗体反应高于单剂,间隔 84 天高于 56 天。
  • 所有组别在疫苗抗原暴露后均出现快速显著免疫应答,提示免疫记忆。

核心结论

  • 研究支持 Ad26.COV2.S 以 5×10^10 vp 进行单剂基础免疫,并在 6 个月间隔后同源加强接种。
  • 1 剂和 2 剂基础免疫均诱导免疫记忆,表现为疫苗抗原暴露后的快速显著应答。

研究设计与样本

  • 随机、双盲、安慰剂对照 2a 期研究,在 18-55 岁和 ≥65 岁成人中开展(NCT04535453)。
  • 评估 4 个剂量水平(1.25×10^10、2.5×10^10、5×10^10 和 1×10^11 vp),单剂和 2 剂方案,以及 56 天和 84 天两种剂量间隔。
  • 基础免疫后 4 或 6 个月给予 Ad26.COV2.S 1.25×10^10 vp 以评估回忆应答。
  • 检测体液和细胞介导免疫应答,并在所有参与者中评估反应原性和安全性。

主要发现

  • 所有 Ad26.COV2.S 方案均诱导体液应答,并呈现剂量反应关系证据。
  • 单剂 Ad26.COV2.S(5×10^10 vp)诱导的抗体和细胞免疫应答至少持续 6 个月。
  • 在 2 剂方案中,相同剂量水平下抗体应答高于 1 剂方案;剂量间隔从 56 天延长至 84 天时免疫应答幅度增加(84 天 vs 56 天)。
  • 所有组别在疫苗抗原暴露后均观察到快速、显著的免疫应答,提示免疫记忆;抗原暴露后至少 6 个月内所有组别均观察到持久免疫应答。
  • 中和抗体与结合抗体之间观察到强且一致的相关性;所有方案后 CD4+ 和 CD8+ T 细胞应答相似;接种后 7 天内反应原性倾向于剂量相关。

临床怎么用

  • 研究支持 Ad26.COV2.S 以 5×10^10 vp 进行单剂基础免疫,并在 6 个月间隔后同源加强接种。
  • 1 剂和 2 剂基础免疫均诱导免疫记忆,疫苗抗原暴露后出现快速显著应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A single dose of Ad26.COV2.S is well-tolerated and effective in preventing moderate-to-severe disease outcomes due to COVID-19. We evaluated the impact of dose level, number of doses, and dose interval on immunogenicity, reactogenicity, and safety of Ad26.COV2.S in adults. Anamnestic responses were also explored. METHODS: This randomised, double-blind, placebo-controlled, Phase 2a study was conducted in adults aged 18-55 years and ≥ 65 years (NCT04535453). Four dose levels (1.25 × 1010, 2.5 × 1010, 5 × 1010, and 1 × 1011 viral particles [vp], single and 2-dose schedules, and dose intervals of 56 and 84 days, were assessed. Four or 6 months post-primary vaccination, Ad26.COV2.S 1.25 × 1010 vp was given to evaluate anamnestic responses. Humoral and cell-mediated immune responses were measured. Reactogenicity and safety were assessed in all participants. RESULTS: All Ad26.COV2.S schedules induced humoral responses with evidence of a dose response relationship. A single dose of Ad26.COV2.S (5 × 1010 vp) induced antibody and cellular immune responses that persisted for up to at least 6 months. In the 2-dose regimens, antibody responses were higher than 1-dose regimens at comparable dose levels, and the magnitude of the immune response increased when the interval between doses was increased (84 days vs 56 days). Rapid, marked immune responses were observed in all groups after vaccine antigen exposure indicating immune memory. Durable immune responses were observed in all groups for up to at least 6 months post-antigen exposure. Strong and consistent correlations between neutralising and binding antibodies were observed CD4 + and CD8 + T cell responses were similar after all regimens. Reactogenicity within 7 days post-vaccination tended to be dose-related. CONCLUSION: The study supports the primary, single dose schedule with Ad26.COV2.S at 5 × 1010 vp and homologous booster vaccination after a 6 month interval. Rapid and marked responses to vaccine antigen exposure indicate induction of immune memory by 1- and 2-dose primary vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cárdenas V, Le Gars M, Truyers C, et al. Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study. Vaccine. 2024. PMID: 38705804. doi:10.1016/j.vaccine.2024.04.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。